Clinical Trial

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Study acronym: ARIEL-ENGIC
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-23; most recent amendment 2026-07-23.
Trial Details
NCT Number NCT07094893
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Collaborators: Merck Serono International SA
Conditions Colorectal Cancer
Enrollment 280 participants
Start Date 2026-09-15
Primary Completion 2028-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-24